Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Who Said Traders and Investor are Emotional Right Now?

Nearing the end of 2019, our research team continues to attempt to dissect the market rally in an effort to present credible research and timely insights to skilled technical traders. We recently authored a research article discussing the potential that the US Stock market is ...
Chris Vermeulen | December 20, 2019 |

Market outlook: is the stock market selloff over?

Last week we explained why the market's short term outlook is bearish. The stock market is now making a pullback, and trade war news isn't helping bulls. Over the past year, tariff-related news has not been good for stocks in the short term. Technicals (short term, nex...
Troy Bombardia | August 7, 2019 |

Why is this Company combining Artificial Intelligence and Psychedelics to address Mental Afflictions

(Click image to play video) Did you know that in Canada, it is estimated that by the age of 40, half of the population will have, or will have had, a mental illness? The recent surge of interest in psychedelic drugs is due to their potential for more effective tr...
Dave Jackson | May 10, 2021 |

Crude Oil Reverses Lower Again After US Missile Attack

Normally, after tensions between Iran/Iraq and the US flare-up, Oil and Gold rally quite extensively but reversed sharply lower by the end of the session. Yes, Gold is 1% higher today and was up over $35 overnight, but Crude Oil has actually moved lower today which is a f...
Chris Vermeulen | January 7, 2020 |

Rare Equity Fund Outflows

STOCK PERFORMANCE FOLLOWING SIMILAR MOVES Retail investors have erred on the side of caution in 2019. From a recent MarketWatch article: Analysts said the “extremely cautious stance” of retail investors this year had been puzzling and acted as a...
Chris Ciovacco | December 3, 2019 |

Retrophin Shares Fall 30% on Failed Phase 3 FORT Study

Shares of Retrophin fell to a 52-week low on the news that topline results from its fosmetpantotenate Phase 3 FORT Study for PKNA treatment failed to meet expectations. Biopharmaceutical firm Retrophin Inc. (RTRX:NASDAQ) shares are trading much lower today as the co...
Streetwise Reports | August 26, 2019 |

FDA Accepts NDA for Global Blood Therapeutics' Sickle Cell Drug; Shares Up 14%

Shares of Global Blood Therapeutics are trading more than 14% higher after the FDA accepted its New Drug Application filing for Voxelotor, a drug used in the treatment of sickle cell disease. Earlier today clinical-stage biopharmaceutical firm Global Blood Therapeuti...
Streetwise Reports | September 6, 2019 |

Protalix Shares Trade up 70% Upon Release of Phase 3 Fabry Disease Data

Shares of Protalix Biotherapeutics skyrocketed today on much higher than average volume as the firm announced positive 12-month interim data from its BRIDGE Phase 3 open label switch-over study of pegunigalsidase alfa (PRX-102) for the treatment of Fabry disease. Earl...
Streetwise Reports | October 18, 2019 |

EyeGate Pharma Shares Looking Up on Pivotal PRK Ocular Bandage Gel Study Data

EyeGate Pharmaceuticals shares opened nearly 85% higher today after the company reported select topline data demonstrating that it met its primary endpoint in its cornea wound repairs pivotal photorefractive keratectomy study using the firm's Ocular Bandage Gel eye drop. ...
Streetwise Reports | November 25, 2019 |

Arbutus Biopharma Trades 25% Higher on Phase 1 Hepatitis B Results

Shares of Arbutus Biopharma traded higher after the company reported significant and continuous reduction in HBsAg in 12 chronic hepatitis B subjects using 60 mg dosage of its AB-729 drug. Clinical-stage biopharmaceutical company Arbutus Biopharma Corp. (ABUS:NASD...
Streetwise Reports | May 20, 2020 |
1 2
USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse
Later
Participate
Not interested